Studies have shown that CCR5 antagonists, especially when combined with immune checkpoint inhibitors or CAR-T cell therapy, can improve immunotherapy outcomes in various cancers, making the CCL5/CCR5 pathway a promising strategy for the treatment of GC (386). This evidence concerns the gene CCR5 and cancer.